Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif. , June 19, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in patients with relapsed/refrac...
With the approval of Andexxa (Andexanet Alfa) came many headaches for those of us in the pharmacy world. The approval process was a bit odd and left us with many questions about safety, efficacy, cost, and post-administration anticoagulation. On top of that, it was made available to only selec...
– Excellent or Good Hemostasis Achieved in 79% of Evaluable Patients with Spontaneous Intracranial Hemorrhage – – Data Featured in an Oral Presentation at the 5 th European Stroke Organisation Conference – SOUTH SAN FRANCISCO, Calif., May 22, 20...
Biotech Pulse The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have struggled since March as the broader healthcare sector ( XLV ) declined following growing momentum amongst the presidential candidates for a universal healthcare plan. This was at a time when the broader ma...
"Man is not what he thinks he is, he is what he hides .” ― André Malraux It has not been a good week for the market as trade tensions have escalated significantly between the U.S. and China. We have seen a slew of Q1 results this week even as equities have staged a cons...
Merck & Co ( MRK ) - The company announced results from the phase 2 study of V114 (15-valent pneumococcal conjugate vaccine) as compared to currently available 13-valent pneumococcal conjugate vaccine in healthy infants 6-12 weeks of age. The primary endpoint was met by demonstrating n...
Portola Pharmaceuticals, Inc. (PTLA) Q1 2019 Earnings Conference Call May 8, 2019 8:30 AM ET Company Participants Cara Miller – Vice President-Investor Relations and Corporate Communications Scott Garland – President and Chief Executive Officer Sheldon Koenig ȁ...
The following slide deck was published by Portola Pharmaceuticals, Inc. in conjunction with their 2019 Q1 earnings Read more ...
Inogen (NASDAQ: INGN ) -31% on Q1 earnings . More news on: Inogen, Inc., Invitae Corporation, 2U, Inc., Stocks on the move, Read more ...
Portola Pharmaceuticals ( PTLA ) Q1 results : Revenues: $22.2M (+236.4%); Collaboration and license revenue: $1.8M (-70.0%). More news on: Portola Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Portola Pharmaceuticals Inc. Company Name:
PTLA Stock Symbol:
NASDAQ Market:
Portola Pharmaceuticals Inc. Website:
SOUTH SAN FRANCISCO, Calif. , May 18, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of stockholders, employees and othe...
SOUTH SAN FRANCISCO, Calif. , May 14, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has proposed extending the New Technology Add-on Payment (NTAP) for Andexxa ® [coagula...
SOUTH SAN FRANCISCO, Calif. , May 11, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today reported financial results for the three months ended March 31, 2020, and provided a corporate update, including the Company's actions to continue to su...